A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53

Journal of Biomolecular Screening

Volumn 18, Issue 2, 2013, Pages 191-198

  Tsuganezawa, Keiko ^a   Nakagawa, Yukari ^a   Kato, Miki ^a   Taruya, Shigenao ^a   Takahashi, Fumio ^a   Endoh, Morio ^a   Utata, Rei ^a   Mori, Masumi ^a   Ogawa, Naoko ^a   Honma, Teruki ^a   Yokoyama, Shigeyuki ^a   Hashizume, Yoshinobu ^a   Aoki, Masaaki ^a   Kasai, Takuma ^a   Kigawa, Takanori ^a   Kojima, Hirotatsu ^b   Okabe, Takayoshi ^b   Nagano, Tetsuo ^b   Tanaka, Akiko ^a  

^a RIKEN   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

fluorescence; Mdm2; MdmX; p53; protein protein interaction

Indexed keywords

ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; P21 ACTIVATED KINASE; PROTEIN MDMX; PROTEIN P53;

APOPTOSIS; ARTICLE; DRUG EFFICACY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

BINDING, COMPETITIVE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872555339     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112460729     Document Type: Article

References (28)

1. Wade M., Wang Y. V., Wahl G. M.. The p53 Orchestra: Mdm2 and Mdmx Set the Tone. Trends. Cell. Biol. 2010 ; 20: 299-309
2. Pietsch E. C., Sykes S. M., McMahon S. B., Murphy M. E.. The p53 Family and Programmed Cell Death. Oncogene. 2008 ; 27: 6507-6521
3. Toledo F., Wahl G. M.. Regulating the p53 Pathway: In Vitro Hypotheses, In Vivo Veritas. Nat. Rev. Cancer. 2006 ; 6: 909-923
4. Alsafadi S., Tourpin S., Andre F., Vassal G., Ahomadegbe J. C.. P53 Family: At the Crossroads in Cancer Therapy. Curr. Med. Chem. 2009 ; 16: 4328-4344
5. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A.. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 2004 ; 303: 844-848
6. Fang S., Jensen J. P., Ludwig R. L., Vousden K. H., Weissman A. M.. Mdm2 Is a RING Finger-Dependent Ubiquitin Protein Ligase for Itself and p53. J. Biol. Chem. 2000 ; 275: 8945-8951
7. Kojima K., Konopleva M., Samudio I. J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L. T., Andreeff M.. MDM2 Antagonists Induce p53-Dependent Apoptosis in AML: Implications for Leukemia Therapy. Blood. 2005 ; 106: 3150-3159
8. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B. T., Qing W., Packman K., Myklebost O., Heimbrook D. C., Vassilev L. T.. Small-Molecule MDM2 Antagonists Reveal Aberrant p53 Signaling in Cancer: Implications for Therapy. Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 1888-1893
9. Laurie N. A., Donovan S. L., Shih C. S., Zhang J., Mills N., Fuller C., Teunisse A., Lam S., Ramos Y., Mohan A., Johnson D., Wilson M., Rodriguez-Galindo C., Quarto M., Francoz S., Mendrysa S. M., Guy R. K., Marine J. C., Jochemsen A. G., Dyer M. A.. Inactivation of the p53 Pathway in Retinoblastoma. Nature. 2006 ; 444: 61-66
10. Shangary S., Qin D., McEachern D., Liu M., Miller R. S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R. B., Pienta K. J., Ling X., Kang S., Guo M., Sun Y., Yang D., Wang S.. Temporal Activation of p53 by a Specific MDM2 Inhibitor Is Selectively Toxic to Tumors and Leads to Complete Tumor Growth Inhibition. Proc. Natl. Acad. Sci. U. S. A. 2008 ; 105: 3933-3938
11. Popowicz G. M., Czarna A., Wolf S., Wang K., Wang W., Domling A., Holak T. A.. Structures of Low Molecular Weight Inhibitors Bound to MDMX and MDM2 Reveal New Approaches for p53-MDMX/MDM2 Antagonist Drug Discovery. Cell Cycle. 2010 ; 9: 1104-1111
12. Patton J. T., Mayo L. D., Singhi A. D., Gudkov A. V., Stark G. R., Jackson M. W.. Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. Cancer Res. 2006 ; 66: 3169-3176
13. Hu B., Gilkes D. M., Farooqi B., Sebti S. M., Chen J.. MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin. J. Biol. Chem. 2006 ; 281: 33030-33035
14. Wade M., Wong E. T., Tang M., Stommel J. M., Wahl G. M.. Hdmx Modulates the Outcome of p53 Activation in Human Tumor Cells. J. Biol. Chem. 2006 ; 281: 33036-33044
15. Garcia D., Warr M. R., Martins C. P., Brown Swigart L., Passegue E., Evan G. I.. Validation of MdmX As a Therapeutic Target for Reactivating p53 in Tumors. Genes Dev. 2011 ; 25: 1746-1757
16. Gu J., Kawai H., Nie L., Kitao H., Wiederschain D., Jochemsen A. G., Parant J., Lozano G., Yuan Z. M.. Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53. J. Biol. Chem. 2002 ; 277: 19251-19254
17. Linares L. K., Hengstermann A., Ciechanover A., Muller S., Scheffner M.. HdmX Stimulates Hdm2-Mediated Ubiquitination and Degradation of p53. Proc. Natl. Acad. Sci. U. S. A. 2003 ; 100: 12009-12014
18. Kawai H., Lopez-Pajares V., Kim M. M., Wiederschain D., Yuan Z. M.. RING Domain-Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity. Cancer Res. 2007 ; 67: 6026-6030
19. Ramos Y. F., Stad R., Attema J., Peltenburg L. T., van der Eb A. J., Jochemsen A. G.. Aberrant Expression of HDMX Proteins in Tumor Cells Correlates with Wild-Type p53. Cancer Res. 2001 ; 61: 1839-1842
20. Danovi D., Meulmeester E., Pasini D., Migliorini D., Capra M., Frenk R., de Graaf P., Francoz S., Gasparini P., Gobbi A., Helin K., Pelicci P. G., Jochemsen A. G., Marine J. C.. Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity. Mol. Cell Biol. 2004 ; 24: 5835-5843
21. Reed D., Shen Y., Shelat A. A., Arnold L. A., Ferreira A. M., Zhu F., Mills N., Smithson D. C., Regni C. A., Bashford D., Cicero S. A., Schulman B. A., Jochemsen A. G., Guy R. K., Dyer M. A.. Identification and Characterization of the First Small Molecule Inhibitor of MDMX. J. Biol. Chem. 2010 ; 285: 10786-10796
22. Wang H., Ma X., Ren S., Buolamwini J. K., Yan C.. A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis. Mol. Cancer Ther. 2011 ; 10: 69-79
23. Mikuni J., Kato M., Taruya S., Tsuganezawa K., Mori M., Ogawa N., Honma T., Yokoyama S., Kojima H., Okabe T., Nagano T., Tanaka A.. A Fluorescence Correlation Spectroscopy-Based Assay for Fragment Screening of Slowly Inhibiting Protein-Peptide Interaction Inhibitors. Anal. Biochem. 2010 ; 402: 26-31
24. Kigawa T., Yabuki T., Matsuda N., Matsuda T., Nakajima R., Tanaka A., Yokoyama S.. Preparation of Escherichia coli Cell Extract for Highly Productive Cell-Free Protein Expression. J. Struct. Funct. Genomics. 2004 ; 5: 63-68
25. Boettcher A., Buschmann N., Furet P., Groell J., Kallen J., Hergovich Lisztwan J., et al. 3-Imidazoyl-Indoles for the Treatment of Proliferative Diseases.. 2008 ;:
26. Kitagawa M., Aonuma M., Lee S. H., Fukutake S., McCormick F.. E2F-1 Transcriptional Activity Is a Critical Determinant of Mdm2 Antagonist-Induced Apoptosis in Human Tumor Cell Lines. Oncogene. 2008 ; 27: 5303-5314
27. Zdzalik M., Pustelny K., Kedracka-Krok S., Huben K., Pecak A., Wladyka B., Jankowski S., Dubin A., Potempa J., Dubin G.. Interaction of Regulators Mdm2 and Mdmx with Transcription Factors p53, p63 and p73. Cell Cycle. 2010 ; 9: 4584-4591
28. Bista M., Smithson D., Pecak A., Salinas G., Pustelny K., Min J., Pirog A., Finch K., Zdzalik M., Waddell B., Wladyka B., Kedracka-Krok S., Dyer M. A., Dubin G., Guy R. K.. On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53. PloS One. 2012 ; 7: e37518